Maveropepimut-S (DPX-Survivac)

The First of IMV’s New Class of Immunotherapies

Generating Cancer-Targeted Killer T Cells

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo.

The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. Survivin plays a critical role in tumor biology as it is associated with tumor cell differentiation, proliferation, invasion and metastasis1. We believe Maveropepimut-S' ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies.

Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions2,3. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients’ quality of life.

DPX Engages Directly with the Immune System - Controlled Release Prevents Systemic Distribution

Multiple Trials To Tackle Hard-to-Treat Cancers

Maveropepimut-S is administered with oral intermittent low-dose cyclophosphamide (CPA), which can act as an immune-modulator increasing the number of survivin-specific T cells generated without inducing significant cytotoxicity. Several studies have demonstrated that such a low dose can have multiple beneficial effects for T cell therapies, including reduction of T regulatory cell numbers and increase in effector T cells.

1 Garg et al. Cancer Cell Int. 2016 Jun 23;16:49.

2 Tanyi et al. American Society of Clinical Oncology Annual Meeting 2019. Poster 5576.

3 Berinstein et al. Oncoimmunology. 2015 May 7;4:e1026529.

Clinical Results

Positive Demonstrated Results for Advanced Recurrent/Refractory Patients

Maveropepimut-S has shown long-lasting clinical benefits with a very favorable safety profile in a heterogenous population of advanced recurrent and/or refractory patients. The population includes older patients or with comorbidities. In all completed and ongoing studies, our candidate has demonstrated a good safety profile and activity on tumors.

1.Weir et al, AACR, 2016

2.Hugues et al, Immunology. 2018

See All Clinical Trials

Very favorable Safety Profile

  • Treatments have been well-tolerated
  • Overall, mostly grade 1-2 events were reported

Activity on Both Liquid & Solid Tumors

  • Tumor regressions in hard to treat solid and liquid tumors (ovarian, DLBCL)
  • Long-lasting clinical responses and benefits (up to 3 years so far)
  • Well suited for different combination regimens

Maveropepimut-S At-a-Glance

IMV's First DPX-Based Cancer Immunotherapy

The unique mechanism of action of the DPX platform allows Antigen Presentation Cells (APCs) to be attracted to the injection site, facilitating antigen presentation in MHC Class I to CD8+ (killer) T cells.

Targeting Survivin Expressed On Cancer Cells

It works by generating a constant flow of killer T cells into the blood to target survivin molecules found on cancer cells.

Evaluated Alone Or In Combination With Merck’s Keytruda®

IMV is investigating the promising combination therapy of Maveropepimut-S/CPA and pembrolizumab in phase 2 clinical trials in patients with Diffuse Large B Cell Lymphoma (DLBCL) and in a basket study across 3 indications.

Market Landscape for Patients Seeking Cancer Treatments

Ovarian Cancer


New cases and 152,000 deaths worldwide each year


Patients who relapse within 3 years of first-line therapy


5-year survival of patients with advanced EOC

Diffuse Large B Cell Lymphoma (DLBCL)

Almost all patients eventually become refractory or resistant to platinum-based therapy ✓10-20% response rates and mPFS of 2.1-3.7 months with current single agents chemotherapy (e.g. doxorubicin, paclitaxel, or topotecan)


New DLBCL cases in the U.S. each year


Patients who eventually become relapsed/refractory patients

3-4 months

Life expectancy of relapsed/refractory DLBCL if left untreated

More details in IMV Corporate Presentation

Source: Adapted from Nature Reviews | Drug Discovery–July 2017
Source:2016 US lymphoid malignancy statistics by World Health Organization subtypes.
Source: 2016SCHOLAR-1(RetrospectiveNon-Hodgkin Lymphoma Research) study,the first, large,systematic, multi-institutional, patient-level meta-analysis of outcomes from 635 patients withchemorefractory diffuse large B-celllymphoma.
Source: Progressive disease after high-dose therapy and autologous transplantation for lymphoidmalignancy: clinical course and patient follow-up. Vose JM, Bierman PJ, Anderson JR, Kessinger A,Pierson J, Nelson J, Frappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO Blood. 1992 Oct 15;80(8):2142-8.